Floatz logo

Alintegimod

Hepatocellular Cancer

7 Hills Pharma, LLCSmall moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Hepatocellular Cancer cohort.

Asset / SponsorPhaseRating
Pregabalin
Sherief Abd-Elsalam
Phase 4BB
Hydroxychloroquine
VA Office of Research and Development
Phase 2B
Tivozanib
AVEO Pharmaceuticals, Inc.
Phase 2B
gsk1120212
Second Affiliated Hospital of Guangzhou Medical University
Phase 2B
Anti-Ny Eso-1 Mtcr Pbl
National Cancer Institute (NCI)
Phase 2B

View all 27 →

Same molecule, other indications

Alintegimod is also rated in:

Anaplastic Lymphoma Kinase Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →
Renal Cell CancerDormant
CCC
Indicative ·
48 / 100
View asset →
ALK Genomic Tumor AberrationsDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →